Argentarii LLC Acquires Shares of 3,452 Edwards Lifesciences Co. (NYSE:EW)

Argentarii LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,452 shares of the medical research company’s stock, valued at approximately $256,000.

A number of other hedge funds also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,150,791.86. This represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,739 shares of company stock valued at $2,799,104 over the last ninety days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 2.0 %

Shares of Edwards Lifesciences stock opened at $70.36 on Monday. The company’s fifty day simple moving average is $72.26 and its 200-day simple moving average is $70.39. The company has a market cap of $41.37 billion, a price-to-earnings ratio of 10.10, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Finally, Evercore ISI cut their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.